14 results about "Propanamide" patented technology

Disclosed herein is a compound that is (R)-(2-(3-((((2-ethylbutanoyl)oxy)methoxy)carbonyl)-2-hydroxyphenyl)-1-propionamidoethyl)boronic acid citrate coordination complex, or a pharmaceutically acceptable salt or solvate thereof. Also disclosed herein are methods of treating a bacterial with a compound that is (R)-(2-(3-((((2-ethylbutanoyl)oxy)methoxy)carbonyl)-2-hydroxyphenyl)-1-propionamidoethyl)boronic acid citrate coordination complex, or a pharmaceutically acceptable salt or solvate thereof in combination with ceftibuten.

The application belongs to the technical field of dental antibacterial materials, and discloses a kind of nanometer composite antibacterial coating for dental material and preparation method thereof.Method: monomer modified arginine, monomer N-isopropyl acrylamide, monomer methyl hexyl acrylate, initiator azobisdimethylamino propanamide hydrochloride, dispersing agent cetyltrimethylammonium bromide and crosslinking agent N,N-methylene bis(acrylamide) are dissolved in water, and the reaction is carried out under protective atmosphere, dialysis, to obtain nanogel dispersion;The nanogel dispersion is mixed with the nanometer zinc oxide dispersion to obtain a nanogel composite zinc oxide antibacterial coating, and a coating is formed after coating.The nanometer composite antibacterial coating for dental material has excellent retention capacity and antibacterial performance.

The application relates to the technical field of drug synthesis, in particular to a synthesis method and application of a 2-(cyclopropylamide)thiazole-4-amide derivative. The thiazole structure is shown in formula I. The preparation method of the 2-(cyclopropylamide)thiazole-4-amide derivative is as follows: the compound shown in formula I is obtained by reacting the compound shown in formula II in the presence of HATU, DIPEA, a primary amine or a secondary amine and tetrahydrofuran. The 2-(cyclopropylamide)thiazole-4-amide derivative has the effect of relieving Alzheimer's disease, and is characterized by strong cholinesterase inhibition activity.

This application relates to a method for preparing (S)-2-((3-((benzo[d][1,3]dioxopenta-5-oxy)methyl)benzyl)-amino)propionamide of formula I or a pharmaceutically acceptable salt thereof, and also to an intermediate for preparing the compound. This method is low-cost, simple to operate, safe and environmentally friendly, exhibits high reaction selectivity and high yield, and is suitable for large-scale industrial production.

This invention discloses a compound for preparing an antiviral drug, its preparation method, and its application, relating to the field of antiviral drug technology. The compound is obtained through a three-step organic synthesis: first, condensation of tert-butyloxycarbonyl-phenylalanine with p-fluorobenzylamine yields tert-butyl(1-((4-fluorobenzyl)amino)-1-oxo-3-phenylprop-2-yl)carbamate; then, deprotection with trifluoroacetic acid yields 2-amino-N-(4-fluorobenzyl)-3-phenylpropionamide; finally, sulfonylation with 5-bromothiophene-2-sulfonylchlorosulfonation gives the final product. This compound specifically targets the influenza virus HA protein, blocking viral invasion of host cells, exhibiting broad-spectrum antiviral activity against influenza A and B viruses, low cytotoxicity, and a mild and controllable preparation process. It can be used to prepare drugs for the prevention and treatment of influenza virus infection, providing a new candidate for the development of new antiviral drugs.

The present application relates to S ) -2-((3-((benzo[ d [1,3]dioxolane-5-oxomethyl)benzyl)-amino)propanamide, to pharmaceutical compositions containing it, and to the use of this crystalline form for the preparation of a medicament for the prevention and / or treatment of pain (e.g. neuropathic pain, including chronic neuropathic pain or neuropathological pain).

The present disclosure provides lyophilates comprising (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate: and pharmaceutical compositions, pharmaceutical formulations, and uses thereof.

This invention discloses a method for preparing 5-methoxy-4,6-dihydroxypyrimidine, relating to the field of 5-methoxy-4,6-dihydroxypyrimidine production technology. N,N-diethyl-2,3,3,3-tetrafluoropropionamide is defluorinated and methoxylated to obtain methyl 2-methoxy-3-(diethylcarbamoyl)propionate; methyl 2-methoxy-3-(diethylcarbamoyl)propionate is cyclized to obtain 5-methoxy-4,6-dihydroxypyrimidine. The method is simple, has low production cost, and is suitable for industrial production.

The present invention relates to compounds of formula (I) as TMEM175 modulators for reducing alpha-synuclein aggregation for the treatment of Parkinson's disease.

This invention proposes a method for preparing chiral α-hydroxy-mercapto-oxime ethers, belonging to the field of organic synthesis technology. The method comprises: S1. protecting the hydroxyl group of chiral α-hydroxypropionamide with a protecting group; S2. reacting the chiral α-protecting group-propionamide sequentially with an oxonium salt donor and an alkoxyamine hydrochloride to obtain chiral 1-[(E)-alkoxynitro]-α-protecting-propyl-1-amine; S3. removing the protecting group from the chiral 1-[(E)-alkoxynitro]-α-protecting-propyl-1-amine to obtain the product. This invention aims to overcome the core defects of existing processes, such as low yield, high impurity content, high reagent safety and environmental risks, high pyridine consumption, and cumbersome operation, and to develop a new process for synthesizing chiral α-hydroxy-mercapto-oxime ethers with high yield, high purity, low cost, high safety, and suitability for industrial scale-up.

The invention relates to the field of fine chemical materials, and provides a preparation method for efficiently preparing an acrylamide monomer with low cost through cracking reaction of beta-amido propanamide compounds under mild conditions by taking alkali as a catalyst for the first time. The whole process is simple to operate, green and environment-friendly.

This document discloses a compound that is a (R)-(2-(3-(((((2-ethylbutyryl)oxy)methoxy)carbonyl)-2-hydroxyphenyl)-1-propamidoethyl)borate citrate coordination complex or a pharmaceutically acceptable salt or solvation thereof. This document also discloses a method for treating bacteria with a compound in combination with cefbromide that is a (R)-(3-(((((2-ethylbutyryl)oxy)methoxy)carbonyl)-2-hydroxyphenyl)-1-propamidoethyl)borate citrate coordination complex or a pharmaceutically acceptable salt or solvation thereof.